 |
The following information is NOT intended to endorse drugs or recommend therapy. While these reviews might be helpful, they are not a substitute for the expertise, skill, knowledge and judgement of healthcare practitioners in patient care.
Learn more about DTIC-Dome.
No reviews have yet been submitted. Be the first to review this drug.
Vical Incorporated (Nasdaq:VICL) announced today that the company will present a case study of its Allovectin® Phase 3 trial at the Phacilitate Cell & Gene...
The recently approved drug vemurafenib (Zelboraf) has been hailed as a breakthrough in the treatment of melanoma, the deadliest form of skin cancer. But...
Recent declines in death rates due to the skin cancer melanoma among white Americans appear to be limited to those with higher levels of education, researchers...
Jan 13, 2012 - Seattle Genetics, Inc. today announced updates to the U.S. Prescribing Information (PI) for Adcetris (brentuximab vedotin). The revised PI...
Québec City, Canada, December 13, 2011 – Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the “Company”) today reported encouraging clinical data for...
Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines & natural products. This material is provided for educational purposes only and is not to be used for medical advice, diagnosis or treatment.
Data sources include Micromedex™ (updated Jan 27th, 2011), Cerner Multum™ (updated Jan 3rd, 2012), Wolters Kluwer™ (updated Jan 31st, 2012) and others.
To view content sources and attributions, refer to our editorial policy.
Copyright © 2000-2012 Drugs.com. All rights reserved.
We comply with the HONcode standard for trustworthy health information.
Verify here
